(2011) investigated the sensitivity of C4‐2 prostate cancer cells to a panel of chemotherapy drugs (doxorubicin, docetaxel, etoposide, cisplatin, and gemcitabine) upon ADAM9 silencing. This evidence concerns the gene ADAM9 and prostate cancer.